The anticancer capacity of the N-allyl-BS and N-(3-mb)-BS was studied while using two phenotypically different cancer cell lines: PTEN-positive (DU145) with normal Akt kinase protein levels and PTEN-negative (PC-3) with high Akt kinase activity. This evidence concerns the gene PTEN and cancer.